AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

(2013) Helen Angell et al.   CURRENT OPINION IN IMMUNOLOGY

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer

(2012) Anna Flammiger et al.   EUROPEAN JOURNAL OF CANCER

Th9 cells promote antitumor immune responses in vivo

(2012) Yong Lu et al.   JOURNAL OF CLINICAL INVESTIGATION

A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma

(2012) Lisa M. Ebert et al.   PLoS One

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

(2011) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Abiraterone prolongs survival in metastatic prostate cancer

(2011) Oliver Sartor   Nature Reviews Clinical Oncology

Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

(2010) S. A. Perez et al.   CLINICAL CANCER RESEARCH

Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers

(2010) Barbara Sperner-Unterweger et al.   IMMUNOBIOLOGY

HER-2/neu as a target for cancer vaccines

(2010) Constantin N Baxevanis et al.   Immunotherapy

TGF-  Induces IL-9 Production from Human Th17 Cells

(2010) G. Beriou et al.   JOURNAL OF IMMUNOLOGY

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers

(2010) M. Ayyoub et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

(2010) Jeremy D. Gates et al.   VACCINE

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

(2009) James L. Gulley et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts

(2009) C. Jandus et al.   CANCER RESEARCH

The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells

(2009) V. Francois et al.   CANCER RESEARCH

Pretreatment frequency of circulating IL-17+CD4+T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients

(2009) Evelyna Derhovanessian et al.   INTERNATIONAL JOURNAL OF CANCER

Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer

(2009) Brian Bierie et al.   JOURNAL OF CLINICAL INVESTIGATION

Human Activated T Lymphocytes Modulate IDO Expression in Tumors through Th1/Th2 Balance

(2009) J. Godin-Ethier et al.   JOURNAL OF IMMUNOLOGY

Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells

(2008) E. Degl'Innocenti et al.   CANCER RESEARCH

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

(2008) M. J.P. Welters et al.   CLINICAL CANCER RESEARCH